SenesTech Inc. Expands Evolve™ Rodent Birth Control Deployment in Baltimore Following Successful Pilot

Reuters
13 Jun
SenesTech Inc. Expands Evolve™ Rodent Birth Control Deployment in Baltimore Following Successful Pilot

SenesTech, Inc., a leader in fertility control solutions for managing animal pest populations, has announced that the City of Baltimore is expanding its use of the company's non-lethal rodent birth control product, Evolve™. Following a successful pilot program, Baltimore has decided to implement a broader deployment of Evolve as part of its integrated pest management $(IPM)$ strategy. The expanded use of Evolve will target areas that showed measurable improvements during the pilot, with plans to add additional sites in collaboration with local pest management teams. Evolve, which limits fertility in male and female rodents, is designed to complement traditional pest control methods and is classified as a minimum-risk pesticide by the EPA. SenesTech will continue to provide training and technical support to Baltimore throughout the rollout.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SenesTech Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA08837) on June 13, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10